Immunocore Holdings (FRA:6YG) LT-Debt-to-Total-Asset: 0.41 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6YG Immunocore Holdings PLC FRA:6YG
77 GF Score
Price €29.80
GF Value €39.46
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings LT-Debt-to-Total-Asset?

Immunocore Holdings FRA:6YG +0.68% 77 LT-Debt-to-Total-Asset is 0.41 as of Mar. 2026. GuruFocus rates FRA:6YG with a GF Score™ of 77/100 and a GF Value™ of €39.46 (Modestly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Immunocore Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.41.

Immunocore Holdings's long-term debt to total assets ratio declined from Mar. 2025 (0.42) to Mar. 2026 (0.41). It may suggest that Immunocore Holdings is progressively becoming less dependent on debt to grow their business.

Immunocore Holdings  (FRA:6YG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Immunocore Holdings LT-Debt-to-Total-Asset Related Terms

Immunocore Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Immunocore Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunocore Holdings LT-Debt-to-Total-Asset Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.21 0.15 0.14 0.43 0.41

Immunocore Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.40 0.39 0.41 0.41
FRA:6YG
77GF Score
Immunocore Holdings PLC FRA:6YG
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunocore Holdings LT-Debt-to-Total-Asset Calculation

Immunocore Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=371.218/911.448
=0.41

Immunocore Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=375.139/927.362
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.41 mean?
Immunocore Holdings (FRA:6YG) has a LT-Debt-to-Total-Asset of 0.41 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Immunocore Holdings and its competitors.
Is Immunocore Holdings' LT-Debt-to-Total-Asset too high?
Immunocore Holdings' current LT-Debt-to-Total-Asset is 0.41. Overall, Immunocore Holdings has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' LT-Debt-to-Total-Asset compare to MAZE and DMRA?
Immunocore Holdings' LT-Debt-to-Total-Asset of 0.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Immunocore Holdings and its competitors. Immunocore Holdings's current LT-Debt-to-Total-Asset is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (FRA:6YG) is currently considered Modestly Undervalued. The stock's GF Value™ is €39.46, compared to a current price of €29.80 — trading 24.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.41. Immunocore Holdings' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Immunocore Holdings (FRA:6YG), the current LT-Debt-to-Total-Asset is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunocore Holdings (FRA:6YG) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of €29.80 is trading 24.5% below its estimated GF Value™ of €39.46. GuruFocus considers Immunocore Holdings to be Modestly Undervalued.

Key valuation signals for FRA:6YG:

  • LT-Debt-to-Total-Asset: 0.41
  • GF Value™: €39.46 vs. price of €29.80 (24.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the FRA:6YG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunocore Holdings Business Description

Other Exchanges IMCR:USA6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
77GF Score

Get the complete analysis for FRA:6YG

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.80
Price
€39.46
GF Value